science
Study Examines Delayed Hepatitis B Vaccination Policy Impacts on Infants
New studies estimate that a recent U.S. policy change delaying hepatitis B vaccination for most infants could result in additional infections and higher health care costs. The policy, adopted late last year, reversed a longstanding recommendation. Separate reports address public trust in science, AI in mental health, and other health developments.
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
last year, the Trump administration adopted a policy recommending a delay in hepatitis B vaccination for most infants. This reversed a 30-year policy associated with a decline in disease cases. The studies are the type typically reviewed by the CDC’s Advisory Committee on Immunization Practices before recommendations.
The committee was replaced with political appointees last year. There is no evidence of adverse effects or safety concerns with the vaccine.
and Addiction Treatment Documents
indicate the Trump administration is opposing harm reduction services for individuals using illicit drugs. A second letter the same day advised against using certain addiction medications without support services. The agency stated this represents a shift away from harm reduction practices that facilitate illicit drug use and are incompatible with federal law.
STAT reported on the implications for addiction treatment evidence.
A survey by the 2026 Edelman Trust Barometer of 16,000 people in 16 countries found that 70% believe at least one of six health claims about food, vaccines, or medicine. Confidence in making informed health decisions or finding health answers has decreased.
Results were consistent across education levels, demographics, and political affiliations. Similar trust levels apply to medical scientists and scientists generally, higher than for journalists at 49% or elected officials at 36%.
